WO2010101750A3 - Salmonella enterica serovar paratyphi a atténuée et ses utilisations - Google Patents

Salmonella enterica serovar paratyphi a atténuée et ses utilisations Download PDF

Info

Publication number
WO2010101750A3
WO2010101750A3 PCT/US2010/025221 US2010025221W WO2010101750A3 WO 2010101750 A3 WO2010101750 A3 WO 2010101750A3 US 2010025221 W US2010025221 W US 2010025221W WO 2010101750 A3 WO2010101750 A3 WO 2010101750A3
Authority
WO
WIPO (PCT)
Prior art keywords
salmonella enterica
enterica serovar
paratyphi
attenuated salmonella
serovar paratyphi
Prior art date
Application number
PCT/US2010/025221
Other languages
English (en)
Other versions
WO2010101750A2 (fr
Inventor
Christofer Vindurampulle
Eileen M. Barry
Myron M. Levine
James Galen
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Priority to ES10749113.6T priority Critical patent/ES2644766T3/es
Priority to EP10749113.6A priority patent/EP2403525B1/fr
Publication of WO2010101750A2 publication Critical patent/WO2010101750A2/fr
Publication of WO2010101750A3 publication Critical patent/WO2010101750A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une souche de S. paratyphi A vivante atténuée, une souche de S. paratyphi A vivante atténuée comprenant un système d'expression plasmidique stabilisé, et un vaccin conjugué contre S. paratyphi, ainsi que des procédés d'utilisation de ces souches et de ce vaccin conjugué.
PCT/US2010/025221 2009-03-06 2010-02-24 Salmonella enterica serovar paratyphi a atténuée et ses utilisations WO2010101750A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES10749113.6T ES2644766T3 (es) 2009-03-06 2010-02-24 Salmonella entérica atenuada serovariedad Parathypy y usos de la misma
EP10749113.6A EP2403525B1 (fr) 2009-03-06 2010-02-24 Salmonella enterica serovar paratyphi a atténuée et ses utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/399,091 US8137930B2 (en) 2005-10-28 2009-03-06 Attenuated Salmonella enterica serovar paratyphi A and uses thereof
US12/399,091 2009-03-06

Publications (2)

Publication Number Publication Date
WO2010101750A2 WO2010101750A2 (fr) 2010-09-10
WO2010101750A3 true WO2010101750A3 (fr) 2011-01-06

Family

ID=42710167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/025221 WO2010101750A2 (fr) 2009-03-06 2010-02-24 Salmonella enterica serovar paratyphi a atténuée et ses utilisations

Country Status (4)

Country Link
US (1) US8137930B2 (fr)
EP (1) EP2403525B1 (fr)
ES (1) ES2644766T3 (fr)
WO (1) WO2010101750A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2148698A4 (fr) * 2007-04-20 2010-12-08 Nucleonics Inc Systeme de complementation hote-vecteur microbien
WO2010083477A2 (fr) * 2009-01-16 2010-07-22 University Of Maryland, Baltimore Vaccin à large spectre contre les salmonelles non typhoïdiques
WO2011060431A2 (fr) 2009-11-16 2011-05-19 University Of Maryland Baltimore Vaccin à vecteur vivant polyvalent dirigé contre une malade associée à clostridium difficile
US9011871B2 (en) 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
EP3156487A4 (fr) * 2014-06-13 2018-01-10 Ouro Fino Saúde Animal Ltda. Vecteur d'expression t7 d'escherichia coli, vecteurs pour la co-expression et la co-purification de polypeptides recombinants dans/avec des protéines porteuses, utilisation de vecteurs d'expression pour l'obtention de complexes avec de multiples antigènes et immunomodulateurs
EP3193918A4 (fr) 2014-09-18 2018-06-20 University of Maryland, Baltimore Vaccin conjugué à large spectre permettant de prévenir des infections par klebsiella pneumoniae et pseudomonas aeruginosa
CN105734001B (zh) * 2014-12-08 2020-04-07 中国人民解放军军事医学科学院生物工程研究所 一种o抗原糖链延长的甲型副伤寒沙门氏菌及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026799A1 (fr) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vaccin conjugue contre la salmonella paratyphi a
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
WO2007053489A2 (fr) * 2005-10-28 2007-05-10 University Of Maryland, Baltimore Salmonella enterica serotype paratyphi a attenue et procedes de son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
US6703233B1 (en) 1998-12-02 2004-03-09 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US8076130B2 (en) 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
ATE463505T1 (de) * 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US20050180985A9 (en) 2001-10-04 2005-08-18 Vladoianu Ion R. Live attenuated salmonella strains for producing monovalent or multivalent vaccines
WO2005042564A1 (fr) 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Proteines de fusion flagelline, comme adjuvants ou vaccins, et procedes d'utilisation
EP1853289A4 (fr) 2005-01-31 2008-04-09 Vaxinnate Corp Nouveaux ligands de polypeptides destines a un recepteur de type toll 2 (tlr2)
WO2007125535A1 (fr) * 2006-05-01 2007-11-08 Biondvax Pharmaceuticals Ltd. Gène de flagelline recombinant et utilisations de celui-ci

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
WO1998026799A1 (fr) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vaccin conjugue contre la salmonella paratyphi a
WO2007053489A2 (fr) * 2005-10-28 2007-05-10 University Of Maryland, Baltimore Salmonella enterica serotype paratyphi a attenue et procedes de son utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRETT, P.J. ET AL.: "Structural and Immunological Characterization of Burkholderia pseudomallei 0-Polysaccharide–Flagellin Protein Conjugates.", INFECTION AND IMMUNITY, vol. 64, no. 7, 1996, pages 2824 - 2828, XP002421921 *
KOMORIYA, K. ET AL.: "Flagellar proteins and type III-exported virulence factors are the predominant proteins secreted into the culture media of Salmonella typhimurium.", MOLECULAR MICROBIOLOGY, vol. 34, no. 4, 1999, pages 767 - 779, XP055097424 *

Also Published As

Publication number Publication date
EP2403525B1 (fr) 2017-09-27
EP2403525A2 (fr) 2012-01-11
WO2010101750A2 (fr) 2010-09-10
ES2644766T3 (es) 2017-11-30
US20120029173A1 (en) 2012-02-02
US8137930B2 (en) 2012-03-20
EP2403525A4 (fr) 2013-04-03

Similar Documents

Publication Publication Date Title
WO2010101750A3 (fr) Salmonella enterica serovar paratyphi a atténuée et ses utilisations
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
WO2007053489A3 (fr) Salmonella enterica serotype paratyphi a attenue et procedes de son utilisation
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
PL387319A1 (pl) Nowy szczep bakterii Salmonella enterica s. Typhimurium, jego zastosowanie i sposób otrzymywania terapeutycznego wektora szczepionkowego
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
WO2012110489A3 (fr) Nouvelle souche de prrsv européenne
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
UA98506C2 (en) Attenuated mycoplasma gallisepticum strains
WO2009058833A3 (fr) Vaccin à mycoplasma bovis et procédés d'utilisation de celui-ci
MX2011010976A (es) Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion.
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX2011008649A (es) Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
CA2763359C (fr) Nouvelles souches de rotavirus humain et nouveaux vaccins
WO2008085406A3 (fr) Vaccin à virus vivant modifié contre haemophilus parasuis (souche jmso)
WO2015051371A3 (fr) Vaccin contre haemophilus parasuis, sérotype 4
NZ589981A (en) Cattle vaccines comprising a disrupted M. bovis bacterium
WO2010083477A3 (fr) Vaccin à large spectre contre les salmonelles non typhoïdiques
GB2515222A (en) Use of flagellin as a vaccine
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso
PH12014501688A1 (en) Influenza c virus and vaccine
WO2011112906A3 (fr) Nouveaux immunogènes et procédés pour la découverte et le dépistage de ceux-ci
WO2010057985A3 (fr) Vaccin marqueur de la salmonelle
WO2013173256A3 (fr) Versions nouvelles et améliorées de vaccins antigrippaux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10749113

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 6277/CHENP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010749113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010749113

Country of ref document: EP